MAST1

Chr 19AD

microtubule associated serine/threonine kinase 1

Also known as: MCCCHCM, SAST

This gene is a member of the microtubule-associated serine/threonine kinase (MAST) family. The protein encoded by this gene has an N-terminal serine/threonine kinase domain followed by a postsynaptic density protein-95/discs large/zona occludens-1 (PDZ) domain. In mouse and rat, the orthologous protein associates with the cytoskeleton and can bind both beta-2-syntrophin and neuronal nitric oxide synthase (nNOS) through its PDZ domain. In mouse and rat, this protein also co-localizes with dystrophin- and utrophin-associated protein complexes (DAPC/UAPC) in the vascular endothelium of the central nervous system. [provided by RefSeq, May 2017]

OMIMResearchGenerating clinical summary…
MultiplemechanismADLOEUF 0.161 OMIM phenotype
Clinical SummaryMAST1
Population Constraint (gnomAD)
Highly constrained gene — heterozygous loss-of-function variants are very rare in the population (pLI 1.00). One damaged copy is likely sufficient to cause disease.
📋
ClinVar Variants
15 unique Pathogenic / Likely Pathogenic· 385 VUS of 720 total submissions

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Dual constrained — LoF & missense intolerant
LoF Constraint?
0.16LOEUF
pLI 1.000
Z-score 6.98
OE 0.08 (0.040.16)
Highly constrained

Highly LoF-intolerant (top ~10% of genes)

Missense Constraint?
5.77Z-score
OE missense 0.50 (0.460.53)
514 obs / 1036.9 exp
Constrained

Extremely missense-constrained (top ~0.01%)

Observed / Expected Ratios?
LoF OE?0.08 (0.040.16)
00.351.4
Missense OE?0.50 (0.460.53)
00.61.4
Synonymous OE?0.82
01.21.6
LoF obs/exp: 5 / 66.3Missense obs/exp: 514 / 1036.9Syn Z: 3.03
Curated Mechanism (G2P)Gene2Phenotype (DDG2P) ↗
strongMAST1-related developmental disorderOTHERAD

This gene — mechanism propensity

DN
0.4289th %ile
GOF
0.5071th %ile
LOF
0.78top 5%

This gene has evidence for multiple mechanisms of pathogenicity (loss-of-function and dominant-negative). Both the Badonyi & Marsh prediction and the broader genomic evidence point to loss-of-function as the predominant mechanism. Different variants in this gene may act through different mechanisms — interpret in context of the specific variant.

LOFprediction above median · LOEUF 0.16
DN1 literature citation

Literature Evidence

DNThe deletion of leu278 was associated with decreased levels of other MAST protein family members, whereas complete loss of Mast1 was associated with increased levels of other MAST proteins. These findings suggested that the leu278 allele acts in a dominant-negative manner.1

Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312. Mechanism ranking also informed by gnomAD constraint, ClinVar, and ClinGen data.

References

  1. 1.PMID 30449657

ClinVar Variant Classifications

720 submitted variants in ClinVar

Classification Summary

Pathogenic5
Likely Pathogenic10
VUS385
Likely Benign257
Benign41
Conflicting14
5
Pathogenic
10
Likely Pathogenic
385
VUS
257
Likely Benign
41
Benign
14
Conflicting

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
1
4
0
0
5
Likely Pathogenic
0
10
0
0
10
VUS
20
344
19
2
385
Likely Benign
1
32
86
138
257
Benign
0
8
14
19
41
Conflicting
14
Total22398119159712

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

20 pathogenic / likely-pathogenic (of 30) ClinVar copy-number / structural variants overlap MAST1 — these span large chromosomal regions, not the gene specifically, and are excluded from the counts above. Explore in CNV tools →

Protein Context — Lollipop Plot

MAST1 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

No active trials found for this gene.

Search ClinicalTrials.gov →